PURA - Puration Advances $100 Million Revenue Strategy As Marijuana Justice Act Is Proposed To Congress
August 08 2017 - 10:21AM
InvestorsHub NewsWire
Dallas, TX
-- August 8, 2017 -- InvestorsHub NewsWire -- Puration, Inc.
(USOTC:
PURA) is preparing for the “inevitability” of
marijuana legalization in the United States. “It’s not if,”
says Brian Shibley, CEO of Puration, “marijuana legalization is
inevitable. It’s only a matter of when. U.S. Senator
Booker’s recent introduction of the Marijuana Justice Act
to legalize marijuana federally and encourage states to legalize
marijuana is yet another indication of the inevitability of
marijuana legalization. Puration will be ready.”
Puration recently acquired a 25-greenhouse grow operation and
signed its first $1.2 million contract with a plan to realize $100
million in potential annual sales. The Company has published
an online presentation that outlines the Company’s overall strategy
to establish itself as the leader in the cannabis extraction market
in conjunction with the ever-evolving landscape of the expansion of
marijuana legalization. The recent acquisition was timed in
conjunction with key events in the legalization of medical
marijuana in Texas. The Company’s extracts are found today in
consumer food and beverages and the Company is making plans for a
pharmaceutical extract that has already received university
research feedback indicating the extract rivals that of GW
Pharmaceuticals (GWPH).
The presentation is available by following the link below:
Puration’s Grow Operation Business
Strategy Overview
To learn more about legalization efforts nationwide, see the recent
article in Power
Engineering featering Hemp, Inc.
(HEMP)
that summarizes the state by state legalization efforts.
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024